Application of four pricing models for orphan medicines: a case study for lumasiran
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Application of four pricing models for orphan medicines: a case study for lumasiran ; volume:19 ; number:1 ; day:23 ; month:12 ; year:2024 ; pages:1-14 ; date:12.2024
Orphanet journal of rare diseases ; 19, Heft 1 (23.12.2024), 1-14, 12.2024
- Klassifikation
-
Wirtschaft
- Urheber
-
Rosenberg, Noa
Manders, Evert
Berg, Sibren van den
Deesker, Lisa J.
Garrelfs, Sander F.
Visser, Saco J. de
Groothoff, Jaap W.
Hollak, Carla E. M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-024-03446-w
- URN
-
urn:nbn:de:101:1-2503032129599.340772743849
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rosenberg, Noa
- Manders, Evert
- Berg, Sibren van den
- Deesker, Lisa J.
- Garrelfs, Sander F.
- Visser, Saco J. de
- Groothoff, Jaap W.
- Hollak, Carla E. M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Framework for the Fair Pricing of Medicines
Pricing and reimbursement of orphan drugs: the need for more transparency
Public spending on orphan medicines: a review of the literature
Variables affecting pricing of orphan drugs: the Italian case
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Price tagging the priceless: International reference pricing for medicines in theory and practice
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
Shining a light in the black box of orphan drug pricing
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Use of biomarkers in the context of orphan medicines designation in the European Union
A Framework for the Fair Pricing of Medicines
Pricing and reimbursement of orphan drugs: the need for more transparency
Public spending on orphan medicines: a review of the literature
Variables affecting pricing of orphan drugs: the Italian case
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Price tagging the priceless: International reference pricing for medicines in theory and practice
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
Shining a light in the black box of orphan drug pricing
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Use of biomarkers in the context of orphan medicines designation in the European Union
A Framework for the Fair Pricing of Medicines
Pricing and reimbursement of orphan drugs: the need for more transparency
Public spending on orphan medicines: a review of the literature
Variables affecting pricing of orphan drugs: the Italian case
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Price tagging the priceless: International reference pricing for medicines in theory and practice
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
Shining a light in the black box of orphan drug pricing
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
Estimating the clinical cost of drug development for orphan versus non-orphan drugs